Trial Profile
Personalized Marker-driven Early Switch to Aflibercept in Patients With Metastatic Colorectal Cancer (PERMAD-Trial) - a Multicenter, Multinational, Two Part, Phase II Trial
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 29 Feb 2024
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary) ; Bevacizumab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Colorectal cancer
- Focus Biomarker; Therapeutic Use
- Acronyms PERMAD
- 20 Jan 2024 Results presented at the 2024 Gastrointestinal Cancers Symposium
- 03 Jan 2022 This trial has been completed in Germany (End Date: 17 Aug 2021), according to European Clinical Trials Database record.
- 17 Jan 2021 Final results presented at the 2021 Gastrointestinal Cancers Symposium.